Anti-IL-5/anti-IL-5R antibody therapy is highly clinically successful in treating severe eosinophilic asthma (SEA), and SEA and chronic obstructive pulmonary disease (COPD), but not in COPD alone. Interleukin-5/interleukin-5-receptor (IL-5/IL-5R) antibodies are anti-eosinophilic medications that have shown effectiveness for individuals with severe eosinophilic asthma (SEA). However, it has not been proven clinically effective for COPD patients. This...